Abstract #2484

The workflow for the validation of USPIO-enhanced MRI for the detection of lymph node metastases in rectal cancer

Rutger C.H. Stijns¹, Bart W.J. Philips¹, Chella van der Post², Iris D. Nagtegaal², Carla Wauters³, Luc J.A. Strobbe⁴, Fatih Polat⁴, Johannes H.W. de Wilt⁵, Stefan H.G. Rietsch^6,7, Sascha Brunheim^6,7, Stephan Orzada⁶, Harald H. Quick^6,7, Jurgen F. Fütterer¹, and Tom W.J. Scheenen^1,6

¹Radiology and Nuclear medicine, Radboudumc, Nijmegen, Netherlands, ²Pathology, Radboudumc, Nijmegen, Netherlands, ³Pathology, Cansius Wilhelmina hospital, Nijmegen, Netherlands, ⁴Surgery, Cansius Wilhelmina hospital, Nijmegen, Netherlands, ⁵Surgery, Radboudumc, Nijmegen, Netherlands, ⁶Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany, ⁷High Field and Hybrid MR Imaging, University Hospital Essen, Essen, Germany

For patients with rectal cancer, the presence of lymph node metastases is an important risk factor for determining prognosis and stratifying for treatment. Clinically, lymph node staging is very challenging, especially when lymph nodes are small (<5mm). By using ultrasmall superparamagnetic iron oxide (USPIO) particles combined with (ultra) high magnetic field imaging (combidex-enhanced MRI), the detection rate of these metastatic lymph nodes may improve significantly. In this abstract we present the workflow for validating combidex-enhanced MRI by performing a node to node comparison of in vivo combidex-enhanced MRI findings with histopathological examination.

This abstract and the presentation materials are available to members only; a login is required.

Join Here